Chronic Hepatitis C
Interferon mitigates steatosis in patients infected with hepatitis C
Published in Hepatitis Weekly, August 25th, 2003
According to recent research published in the journal Hepatology, "it has been suggested that hepatitis C virus (HCV) and especially genotype 3 is associated with steatosis. We assessed the effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis. We analyzed 1,428 naive patients included in a randomized trial."
"A single pathologist scored steatosis at baseline and 24 weeks after the treatment. At baseline, steatosis was present in 935 of 1428 patients (65%), including 175 (83%) of 210 patients with genotype 3 versus 760 (62%) of 1218 with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-08-25)
More Articles from Hepatitis Weekly
- Chronic Hepatitis C
Pegylated interferon has improved the outlook for many hepatitis patients - Hepatitis B Virus
HBV DNA persists several years after liver transplantation despite prophylaxis - Vector Development
FLAP lentiviral vectors augment ex vivo gene transfer to liver cells - Virology
Alcohol increases the expression of hepatitis C virus replicons - Virology
Donor or recipient HCV infections can predominate after liver transplantation - Virology
Vesicular stomatitis virus is oncolytic in hepatocellular carcinoma models - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
